SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 254 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,240,516 | -8.5% | 734,150 | -0.2% | 0.00% | 0.0% |
| Q2 2023 | $22,111,775 | -13.1% | 735,588 | +4.7% | 0.00% | -20.0% |
| Q1 2023 | $25,448,641 | +0.2% | 702,419 | -1.4% | 0.01% | 0.0% |
| Q4 2022 | $25,409,060 | +8.7% | 712,337 | +3.2% | 0.01% | 0.0% |
| Q3 2022 | $23,377,000 | +16.9% | 690,583 | -0.1% | 0.01% | +25.0% |
| Q2 2022 | $19,993,000 | -1.6% | 691,331 | +9.9% | 0.00% | 0.0% |
| Q1 2022 | $20,326,000 | +6.6% | 628,880 | -3.8% | 0.00% | +33.3% |
| Q4 2021 | $19,066,000 | +8.6% | 653,838 | -0.7% | 0.00% | 0.0% |
| Q3 2021 | $17,564,000 | -15.4% | 658,552 | -2.3% | 0.00% | -25.0% |
| Q2 2021 | $20,761,000 | +34.4% | 674,248 | +14.3% | 0.00% | +33.3% |
| Q1 2021 | $15,442,000 | -0.2% | 589,857 | -4.1% | 0.00% | 0.0% |
| Q4 2020 | $15,467,000 | +14.6% | 614,766 | -5.1% | 0.00% | 0.0% |
| Q3 2020 | $13,495,000 | -15.6% | 647,584 | -3.9% | 0.00% | -25.0% |
| Q2 2020 | $15,997,000 | +29.0% | 673,593 | -2.3% | 0.00% | 0.0% |
| Q1 2020 | $12,402,000 | -22.0% | 689,361 | +2.9% | 0.00% | 0.0% |
| Q4 2019 | $15,891,000 | -15.1% | 669,967 | -1.7% | 0.00% | 0.0% |
| Q3 2019 | $18,724,000 | -14.5% | 681,391 | +2.9% | 0.00% | -20.0% |
| Q2 2019 | $21,907,000 | -4.8% | 662,051 | +0.8% | 0.01% | -16.7% |
| Q1 2019 | $23,017,000 | +6.1% | 656,896 | +0.6% | 0.01% | 0.0% |
| Q4 2018 | $21,702,000 | -34.6% | 653,287 | -0.9% | 0.01% | -25.0% |
| Q3 2018 | $33,194,000 | -12.9% | 659,270 | +3.6% | 0.01% | -20.0% |
| Q2 2018 | $38,100,000 | +35.4% | 636,597 | +3.6% | 0.01% | +42.9% |
| Q1 2018 | $28,141,000 | +9.5% | 614,446 | -4.7% | 0.01% | 0.0% |
| Q4 2017 | $25,689,000 | -0.9% | 644,662 | -0.5% | 0.01% | 0.0% |
| Q3 2017 | $25,916,000 | -8.0% | 647,900 | -0.8% | 0.01% | -12.5% |
| Q2 2017 | $28,155,000 | +41.6% | 653,262 | +2.8% | 0.01% | +33.3% |
| Q1 2017 | $19,889,000 | +26.0% | 635,426 | +1.6% | 0.01% | +20.0% |
| Q4 2016 | $15,788,000 | -16.8% | 625,218 | -18.5% | 0.01% | -16.7% |
| Q3 2016 | $18,969,000 | +44.1% | 767,014 | +18.6% | 0.01% | +50.0% |
| Q2 2016 | $13,168,000 | +68.4% | 646,452 | +24.7% | 0.00% | +33.3% |
| Q1 2016 | $7,819,000 | +44.2% | 518,374 | +28.4% | 0.00% | +50.0% |
| Q4 2015 | $5,424,000 | +0.9% | 403,603 | +5.3% | 0.00% | 0.0% |
| Q3 2015 | $5,375,000 | -9.8% | 383,179 | +9.2% | 0.00% | 0.0% |
| Q2 2015 | $5,958,000 | +57.5% | 350,859 | +12.1% | 0.00% | +100.0% |
| Q1 2015 | $3,784,000 | +56.4% | 313,023 | +7.3% | 0.00% | 0.0% |
| Q4 2014 | $2,420,000 | -9.4% | 291,637 | -5.1% | 0.00% | 0.0% |
| Q3 2014 | $2,672,000 | +3.4% | 307,468 | +30.3% | 0.00% | 0.0% |
| Q2 2014 | $2,583,000 | +42.4% | 235,970 | +16.3% | 0.00% | 0.0% |
| Q1 2014 | $1,814,000 | +7.4% | 202,868 | -9.4% | 0.00% | 0.0% |
| Q4 2013 | $1,689,000 | +15.4% | 223,987 | +12.2% | 0.00% | 0.0% |
| Q3 2013 | $1,463,000 | +114.2% | 199,603 | +87.9% | 0.00% | – |
| Q2 2013 | $683,000 | – | 106,238 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |